Wolverine Trading
NKTR icon

Wolverine Trading’s Nektar Therapeutics NKTR Stock Holding History

Wolverine Trading’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$3.4M Buy
57,758
+42,686
+283% +$1.41M ﹤0.01% 1716
2025
Q2 		$388K Buy
15,072
+14,092
+1,438% +$158K ﹤0.01% 3199
2025
Q1 		$10.9K Buy
+980
New +$12.8K ﹤0.01% 4604
2022
Q2 		– Sell
-1,081
Closed -$68.2K – 5322
2022
Q1 		$90K Sell
1,081
-2,185
-67% -$323K ﹤0.01% 4867
2021
Q4 		$686K Sell
3,266
-199
-6% -$43.2K ﹤0.01% 3060
2021
Q3 		$932K Sell
3,465
-3,336
-49% -$802K ﹤0.01% 3077
2021
Q2 		$1.78M Buy
6,801
+866
+15% +$240K ﹤0.01% 2105
2021
Q1 		$1.74M Buy
5,935
+2,557
+76% +$796K ﹤0.01% 2083
2020
Q4 		$909K Sell
3,378
-113
-3% -$29.2K ﹤0.01% 2486
2020
Q3 		$884K Sell
3,491
-89
-2% -$28K ﹤0.01% 2201
2020
Q2 		$1.2M Sell
3,580
-933
-21% -$291K ﹤0.01% 1829
2020
Q1 		$1.22M Buy
4,513
+47
+1% +$14.5K ﹤0.01% 1747
2019
Q4 		$1.39M Sell
4,466
-483
-10% -$140K ﹤0.01% 2121
2019
Q3 		$1.33M Buy
4,949
+4,531
+1,084% +$1.66M ﹤0.01% 1742
2019
Q2 		$223K Buy
+418
New +$210K ﹤0.01% 3602
2019
Q1 		– Sell
-551
Closed -$327K – 5042
2018
Q4 		$278K Buy
+551
New +$333K ﹤0.01% 3279
2018
Q1 		– Sell
-2,129
Closed -$2.74M – 5597
2017
Q4 		$1.91M Buy
+2,129
New +$1.26M 0.01% 1595
2017
Q3 		– Sell
-674
Closed -$211K – 4813
2017
Q2 		$195K Buy
+674
New +$195K ﹤0.01% 3612
2017
Q1 		– Sell
-1,314
Closed -$242K – 4757
2016
Q4 		$242K Buy
1,314
+162
+14% +$32.9K ﹤0.01% 3507
2016
Q3 		$293K Buy
+1,152
New +$297K ﹤0.01% 3266

Other funds holding NKTR

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wolverine Trading's NKTR Position: Q3 2025 in Review

Wolverine Trading increased its Nektar Therapeutics (NKTR) stake by 283% in Q3 2025, buying an estimated $1.41M and bringing the position to 57,758 shares worth $3.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1716.

Wolverine Trading first reported a position in NKTR in Q3 2016 and has held it in 20 quarters since. 154 funds tracked by Wall St. Rank hold NKTR as of Q3 2025.

  • Wolverine Trading held 57,758 shares of Nektar Therapeutics worth $3.4M as of Q3 2025.
  • Wolverine Trading bought 42,686 Nektar Therapeutics shares in Q3 2025, an estimated $1.41M.
  • Nektar Therapeutics made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #1716 holding.
  • Wolverine Trading first reported a position in Nektar Therapeutics in Q3 2016 and has held it in 20 quarters since.
  • 154 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.